NCT01505608 2024-08-06
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT01582152 2019-06-05
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02047214 2018-01-31
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT01113463 2016-10-31
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00479635 2014-01-22
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT00553813 2014-01-22
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
Cortice Biosciences, Inc.
Phase 2 Terminated